#1 Clinical Trials Search in Europe

3-Amino-N-{[5-[4-[Bis[(2S,3R,4R,5R)-2,3,4,5,6-Pentahydroxyhexyl]Amino]Piperidine-1-Carbonyl]-1,3-Diethyl-Benzimidazol-1-Ium-2-Yl]Methyl}-5H-Pyrrolo[2,3-B]Pyrazine-2-Carboxamide Dihydrochloride Chloride

This article discusses the clinical trials of ETD001, an innovative inhaled medication being studied for the treatment of cystic fibrosis (CF). ETD001 is a nebulizer solution containing the active substance 3-Amino-N-{[5-[4-[Bis[(2S,3R,4R,5R)-2,3,4,5,6-Pentahydroxyhexyl]Amino]Piperidine-1-Carbonyl]-1,3-Diethyl-Benzimidazol-1-Ium-2-Yl]Methyl}-5H-Pyrrolo[2,3-B]Pyrazine-2-Carboxamide Dihydrochloride Chloride. The trials aim to evaluate the safety, effectiveness, and how the body processes this new drug in people with CF.

Table of Contents

Introduction to ETD001

ETD001 is a new investigational drug being developed for the treatment of cystic fibrosis (CF). Its full chemical name is 3-amino-N-{[5-[4-[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]piperidine-1-carbonyl]-1,3-diethyl-benzimidazol-1-ium-2-yl]methyl}-5H-pyrrolo[2,3-b]pyrazine-2-carboxamide dihydrochloride chloride.[1] This complex name reflects its unique chemical structure, which is designed to target specific aspects of CF.

How ETD001 Works

While the exact mechanism of action is not fully described in the available information, ETD001 is likely designed to address the underlying causes of CF. Cystic fibrosis is a genetic disorder that affects the lungs and other organs, causing thick, sticky mucus to build up. ETD001 may work by helping to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is defective in people with CF, or by addressing other aspects of the disease process.[1]

Administration of ETD001

ETD001 is administered as a nebulizer solution, which means it is inhaled directly into the lungs using a special device called the eFlow® Nebulizer System. This system converts the liquid medication into a fine mist that can be easily breathed in. The nebulizer is described as quiet, lightweight, and battery-operated, making it convenient for patients to use.[1]

Current Clinical Trial

A clinical trial is currently underway to evaluate ETD001. This study is designed in two parts:[1]

  • Part A: This initial phase will assess the safety and tolerability of repeated inhaled doses of ETD001 compared to a placebo. It will also look at how the drug is processed by the body (pharmacokinetics).
  • Part B: This phase will evaluate the effectiveness of ETD001 in improving lung function, specifically looking at a measure called forced expiratory volume in 1 second (FEV1). FEV1 is a key indicator of lung health in CF patients.

Eligibility Criteria

The trial has specific criteria for who can participate. Some key points include:[1]

  • Participants must be 18 years or older
  • Have a confirmed diagnosis of cystic fibrosis
  • Have moderately impaired lung function (FEV1 between 40% and 90% of predicted normal)
  • Be clinically stable, without recent significant changes in their CF symptoms or treatments

There are also several exclusion criteria, such as certain liver or kidney function abnormalities, recent use of certain medications, or presence of specific co-existing conditions.

Potential Benefits

While it’s important to note that the effectiveness of ETD001 is still being studied, the researchers hope to see improvements in several areas:[1]

  • Improved lung function, as measured by FEV1 and other breathing tests
  • Better quality of life, as assessed by a CF-specific questionnaire
  • Potentially, improvements in other aspects of CF not yet specified in the available information

Safety Considerations

As with any new medication, safety is a primary concern. The study is designed to carefully monitor for any side effects or adverse events. Participants will undergo regular check-ups, including physical exams, lab tests, and ECGs (heart tests). The study is “double-blind,” meaning neither the participants nor the researchers know who is receiving ETD001 and who is receiving the placebo. This helps ensure unbiased results.[1]

It’s important to remember that ETD001 is still an experimental drug. While it shows promise, its full benefits and potential risks are not yet known. Patients with CF should continue to follow their current treatment plans and consult with their healthcare providers about any new treatment options.

Aspect Details
Drug Name ETD001
Administration Inhaled via eFlow® Nebulizer System
Condition Cystic Fibrosis
Trial Design Randomized, Double-Blind, Placebo-Controlled, Two-Part Study
Primary Objectives Assess safety, tolerability, and effect on lung function (FEV1)
Secondary Objectives Evaluate pharmacokinetics, other lung function measures, quality of life
Participant Age 18 years and older
Key Inclusion Criteria Confirmed CF diagnosis, FEV1 40-90% predicted, clinically stable
Treatment Duration Part A: 7 days; Part B: Two 28-day periods with washout
Dosage 4.5 mg twice daily

FAQ

  • What is ETD001 and how is it administered? ETD001 is an experimental inhaled medication for cystic fibrosis. It's given as a nebulizer solution, which means it's turned into a fine mist that patients breathe in using a special device called the eFlow® Nebulizer System.
  • What are the main goals of the ETD001 clinical trials? The trials aim to assess the safety, tolerability, and effectiveness of ETD001 in people with cystic fibrosis. They also want to understand how the drug moves through the body (pharmacokinetics) and its effects on lung function.
  • Who can participate in these clinical trials? The trials are open to adults (18 years and older) with confirmed cystic fibrosis diagnosis. Participants must have specific lung function measurements and be clinically stable. There are other inclusion and exclusion criteria that the study team will review with potential participants.
  • How long do the treatment periods last in the trials? There are two parts to the trial. In Part A, participants receive treatment for 7 days. In Part B, there are two 28-day treatment periods with a wash-out period in between.
  • What measurements will be taken during the trials? The trials will measure changes in lung function (especially FEV1), safety assessments (like ECG, vital signs, and lab tests), quality of life (using a questionnaire called CFQ-R), and levels of the drug in blood and urine.

Ongoing Clinical Trials on 3-Amino-N-{[5-[4-[Bis[(2S,3R,4R,5R)-2,3,4,5,6-Pentahydroxyhexyl]Amino]Piperidine-1-Carbonyl]-1,3-Diethyl-Benzimidazol-1-Ium-2-Yl]Methyl}-5H-Pyrrolo[2,3-B]Pyrazine-2-Carboxamide Dihydrochloride Chloride

  • Study on the Effects of Inhaled ETD001 for People with Cystic Fibrosis

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy

Glossary

  • Cystic Fibrosis (CF): A genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It causes the body to produce thick and sticky mucus that can clog the lungs and obstruct the pancreas.
  • FEV1: Forced Expiratory Volume in 1 second. It's a measure of how much air a person can exhale during a forced breath in one second. It's an important test of lung function.
  • Nebulizer: A device that turns liquid medicine into a fine mist that can be inhaled into the lungs.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Spirometry: A common test used to assess how well your lungs work by measuring how much air you inhale and exhale, and how quickly you exhale.
  • Double-blind study: A type of clinical trial where neither the participants nor the researchers know who is receiving the experimental treatment and who is receiving a placebo or standard treatment.
  • Placebo: A substance that has no therapeutic effect, used as a control in testing new drugs.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Wash-out period: A period of time during a clinical study when participants are taken off a treatment to eliminate any residual effects before starting a new treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-inhaled-etd001-for-people-with-cystic-fibrosis/